Your browser doesn't support javascript.
loading
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.
Nester, Carla; Appel, Gerald B; Bomback, Andrew S; Bouman, Koenraad Peter; Cook, H Terence; Daina, Erica; Dixon, Bradley P; Rice, Kara; Najafian, Nader; Hui, James; Podos, Steven D; Langman, Craig B; Lightstone, Liz; Parikh, Samir V; Pickering, Matthew C; Sperati, C John; Trachtman, Howard; Tumlin, James; de Vries, Aiko Pj; Wetzels, Jack F M; Remuzzi, Giuseppe.
Affiliation
  • Nester C; Divisions of Nephrology, Stead Family Children's Hospital, University of Iowa, Iowa City, Iowa, USA.
  • Appel GB; Department of Medicine, Division of Nephrology, Columbia University Irving Medical Center, New York, New York, USA.
  • Bomback AS; Department of Medicine, Division of Nephrology, Columbia University Irving Medical Center, New York, New York, USA.
  • Bouman KP; ZNA Nierkliniek, Antwerp, Belgium.
  • Cook HT; Department of Immunology and Inflammation, Centre for Inflammatory Disease, Faculty of Medicine, Imperial College London, London, UK.
  • Daina E; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
  • Dixon BP; Department of Pediatrics, Renal Section, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Rice K; Alexion, AstraZeneca Rare Diseases, Boston, Massachusetts, USA.
  • Najafian N; Alexion, AstraZeneca Rare Diseases, Boston, Massachusetts, USA.
  • Hui J; Alexion, AstraZeneca Rare Diseases, Boston, Massachusetts, USA.
  • Podos SD; Discovery research in small molecule research, Alexion, AstraZeneca Rare Diseases, New Haven, Connecticut, USA.
  • Langman CB; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Lightstone L; Department of Immunology and Inflammation, Centre for Inflammatory Disease, Faculty of Medicine, Imperial College London, London, UK.
  • Parikh SV; Division of Nephrology, The Ohio State University Medical Center, Columbus, Ohio, USA.
  • Pickering MC; Department of Immunology and Inflammation, Centre for Inflammatory Disease, Faculty of Medicine, Imperial College London, London, UK.
  • Sperati CJ; Johns Hopkins University School of Medicine, Division of Nephrology, Baltimore, Maryland, USA.
  • Trachtman H; Department of Pediatrics, NYU Grossman School of Medicine, New York, New York, USA.
  • Tumlin J; Georgia Nephrology, Lawrenceville, Georgia, USA.
  • de Vries AP; Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
  • Wetzels JFM; Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Remuzzi G; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Am J Nephrol ; 53(10): 687-700, 2022.
Article in En | MEDLINE | ID: mdl-36423588
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glomerulonephritis, Membranoproliferative / Kidney Diseases Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Am J Nephrol Year: 2022 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glomerulonephritis, Membranoproliferative / Kidney Diseases Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Am J Nephrol Year: 2022 Type: Article Affiliation country: United States